Endometriosis Guidelines Compared: What Every Woman Should Know

Why Guideline Comparison Matters for Your Care

The three bodies whose documents shape most clinical decisions are the American College of Obstetricians and Gynecologists (ACOG), the European Society of Human Reproduction and Embryology (ESHRE), and the American Society for Reproductive Medicine (ASRM). They do not always agree, and where they disagree, your doctor's recommendation will differ depending on which guideline she was trained on.

Endometriosis affects an estimated 10% of women of reproductive age globally, roughly 190 million people. Despite that prevalence, women routinely wait years for a diagnosis. A 2011 survey across eight countries found a mean diagnostic delay of 6.7 years, a figure that has barely shifted in the decade since. Knowing which guidelines your clinician is following, and where those guidelines have gaps, is the first step toward shortening that wait for yourself.

What the three guidelines share

All three organizations agree on several core points. Laparoscopy with histological confirmation remains the definitive diagnostic standard. Endometriosis is a chronic, estrogen-dependent inflammatory disease. Medical therapy does not cure the condition but can manage symptoms effectively. Surgical excision is preferred over ablation when surgery is chosen.

Where they diverge

The sharpest disagreement is on empiric diagnosis: treating based on symptoms and imaging findings alone, without laparoscopy. ESHRE's 2022 guideline explicitly recommends offering empiric hormonal treatment to women with a clinical presentation consistent with endometriosis if they do not want surgery or surgery carries unacceptable risk. ACOG's 2018 practice bulletin takes a similar position for pain management, but remains more cautious about skipping surgical confirmation in women pursuing fertility treatment. ASRM's guidance focuses most sharply on the fertility context.

How Each Guideline Approaches Diagnosis

Diagnosis is where guideline differences affect you most immediately. Depending on which framework your clinician uses, you may be offered treatment empirically or told you need a camera inside your abdomen before any hormones are prescribed.

ESHRE 2022: clinical diagnosis is sufficient to start treatment

ESHRE states that a negative laparoscopy does not definitively exclude endometriosis, and a positive one is not required before empiric medical treatment begins. The 2022 ESHRE guideline recommends transvaginal ultrasound as the first imaging step for women with suspected deep infiltrating or ovarian endometriosis. MRI adds value for mapping disease extent, particularly rectovaginal and ureteral involvement, but neither imaging modality is sensitive enough to rule out peritoneal disease.

ACOG 2018: empiric treatment is acceptable for pain, surgery for fertility

ACOG Practice Bulletin 114 allows empiric hormonal suppression in women with suspected endometriosis and dysmenorrhea, but recommends diagnostic laparoscopy before assisted reproduction in most cases. The bulletin also notes that CA-125 is not recommended as a screening or diagnostic test because of poor sensitivity in early-stage disease.

ASRM 2014 and updated guidance: surgery confirms and stages

ASRM places more emphasis on surgical staging using the revised American Fertility Society (rAFS) classification. The ASRM practice committee opinion argues that knowing the stage matters for counseling about natural conception versus IVF. Stage III-IV disease carries a meaningfully different prognosis than Stage I-II.

The diagnostic delay problem across all three frameworks

No guideline has solved the 7-year delay. All three acknowledge it; none offers a pathway that eliminates it. ESHRE is the most aggressive in trying to shorten it by permitting empiric treatment, but even that approach requires a clinician who is willing to make a clinical diagnosis. Primary care providers, who see most women first, often lack training in recognizing endometriosis, and none of the three guidelines includes a primary-care screening protocol.

Medical Treatment Options by Life Stage

Endometriosis management is not one-size-fits-all. What is appropriate at 22 differs markedly from what is appropriate at 42. All guidelines organize treatment around two axes: symptom control and fertility goals.

Reproductive years (roughly ages 18-40), not trying to conceive

First-line therapy across all three guidelines is a combined oral contraceptive (COC) or a progestin-only agent. COCs suppress ovulation and reduce endometrial proliferation. Evidence from the Zito 2007 Cochrane review shows COCs significantly reduce dysmenorrhea compared with placebo. Progestins, including norethindrone acetate 5 mg daily, medroxyprogesterone acetate, and the 52 mg levonorgestrel-releasing IUD (Mirena), are alternatives with similar efficacy and are appropriate when estrogen is contraindicated.

The levonorgestrel IUD deserves particular mention. The Abou-Setta 2006 analysis and subsequent data suggest it reduces endometriosis-associated pain as effectively as GnRH agonists in some populations, with far fewer systemic side effects. ESHRE gives it a strong recommendation. ACOG lists it as an option. ASRM endorses it specifically for women who want long-acting contraception alongside symptom control.

Second-line therapy across all three guidelines is a GnRH agonist (leuprolide acetate, nafarelin, goserelin) or a GnRH antagonist (elagolix, relugolix). These agents produce a hypoestrogenic state that suppresses endometriosis activity. The trade-off is bone mineral density loss.

GnRH therapy and bone density: what the guidelines say

ESHRE, ACOG, and ASRM all require add-back therapy (low-dose estrogen plus progestin, or norethindrone acetate alone at 5 mg daily) after no more than 6 months of GnRH agonist monotherapy. The FDA label for leuprolide acetate specifies this limit and notes that bone density loss may not be fully reversible. Add-back does not meaningfully reduce pain relief while protecting the skeleton.

Elagolix (Orilissa) is the first oral GnRH antagonist approved specifically for endometriosis pain. The ELARIS EM-I trial showed that 150 mg once daily reduced dysmenorrhea in 46.4% of women versus 22.7% on placebo, and 200 mg twice daily reduced it in 75.8%. Bone density loss with the higher dose averaged 2.6% at the lumbar spine after 6 months of use, which underscores the add-back requirement.

Trying to conceive

This is the stage where guideline differences are most consequential. ESHRE and ACOG agree that hormonal suppression does not improve natural conception rates and should not be used while a woman is trying to conceive. Medical therapy is not a bridge to pregnancy. Surgery may be.

The Jacobson 2010 Cochrane review found that laparoscopic surgery for Stage I-II endometriosis increased the live birth rate compared with diagnostic laparoscopy alone (odds ratio 1.66). The effect for Stage III-IV disease is less clear. ASRM recommends surgical treatment of endometriomas larger than 4 cm before IVF, primarily to improve oocyte access, though Garcia-Velasco 2004 data suggests smaller endometriomas may not reduce IVF outcomes significantly.

Women with endometriosis who pursue IVF should know that a 2014 meta-analysis in Fertility and Sterility found a 21% reduction in clinical pregnancy rate per cycle compared with tubal-factor infertility patients. This is a meaningful difference, and your reproductive endocrinologist should account for it in setting realistic expectations.

Perimenopause (typically ages 45-55)

Here is a stage all three guidelines underserve. Most endometriosis trials enrolled women under 45. Perimenopausal women face a specific problem: fluctuating estrogen levels can trigger flares even as the menstrual cycle becomes irregular. None of the three major guidelines provides explicit perimenopausal dosing protocols.

A practical clinical framework for perimenopausal women with endometriosis:

• If hormonal suppression is still needed, a progestin-dominant approach (norethindrone acetate or the levonorgestrel IUD) is preferable to a GnRH agonist, which adds bone loss to a skeleton already entering the menopause transition.
• COCs remain an option if cardiovascular risk is acceptable, but thrombotic risk rises after 40.
• If surgery was previously performed and disease is excised, low-dose menopausal hormone therapy (MHT) after confirmed menopause is generally safe, using a progestin-containing regimen to protect against any residual ectopic tissue.
• ACOG and The Menopause Society both note that MHT after hysterectomy with bilateral salpingo-oophorectomy for endometriosis should include a progestin component (or tibolone where available) rather than estrogen alone, because residual ectopic tissue can respond to unopposed estrogen.

Postmenopause

Endometriosis does not always burn out at menopause. Remorgida 2007 documented postmenopausal endometriosis activity in women on estrogen-only MHT. ACOG and ESHRE advise using combined (estrogen plus progestogen) MHT rather than estrogen alone in women with a history of endometriosis, even after hysterectomy. This is a clinically important point that many providers miss when they default to estrogen-only regimens post-hysterectomy.

Surgical Treatment: When Guidelines Agree and When They Do Not

Surgery is not optional for all women, and the guidelines offer reasonably convergent advice here.

Excision versus ablation

All three guidelines prefer excision of endometriotic lesions over ablation (burning). The Pundir 2017 systematic review found excisional surgery associated with better pain outcomes and lower recurrence rates than ablation alone. ESHRE gives excision a Grade A recommendation. ACOG states a preference for excision without formally grading it. ASRM recommends excision or ablation as equivalent for superficial peritoneal disease but excision for deep infiltrating disease.

Hysterectomy with bilateral salpingo-oophorectomy

Definitive surgery (hysterectomy plus BSO) is appropriate for women who have completed childbearing and have severe, refractory disease. ACOG notes that BSO reduces recurrence risk but is not curative, and 10-15% of women report symptom recurrence even after BSO, likely from residual peritoneal deposits. The Shakiba 2008 data found a 62% reduction in reoperation rates with BSO versus hysterectomy alone.

Endometrioma management before IVF

ESHRE advises caution before operating on endometriomas in women with prior ovarian surgery, citing the risk of diminished ovarian reserve. The Raffi 2012 study found that ovarian reserve (measured by anti-Mullerian hormone) dropped by approximately 38% after unilateral endometrioma surgery. For women with bilateral endometriomas or prior unilateral surgery, the decision to operate before IVF requires individualized risk discussion with a reproductive endocrinologist.

Pregnancy, Lactation, and Contraception

This section addresses both women who are trying to avoid pregnancy on hormonal therapy and those who are trying to achieve it.

Hormonal suppression drugs: pregnancy safety

All GnRH agonists and antagonists are contraindicated in pregnancy. Leuprolide acetate is FDA Pregnancy Category X. Elagolix (Orilissa) carries a boxed warning: pregnancy must be excluded before starting, and reliable contraception (non-estrogen-containing, given that elagolix reduces COC efficacy at the 200 mg twice-daily dose) is required throughout treatment. The FDA Orilissa prescribing information notes that elagolix may compromise the effectiveness of combined oral contraceptives, making barrier methods or non-hormonal IUD the preferred contraceptive option during elagolix use.

Norethindrone acetate and medroxyprogesterone acetate are both contraindicated in pregnancy. Progestins taken in early pregnancy have not been definitively linked to fetal harm at low doses in observational data, but the risk is uncertain and exposure should be avoided.

Danazol, an older androgen-derived therapy now rarely used, is absolutely contraindicated in pregnancy due to virilization of a female fetus.

Lactation

GnRH agonists are not recommended during breastfeeding because the systemic hypoestrogenic state they create could suppress milk production. Progestins (norethindrone acetate, medroxyprogesterone) are generally compatible with breastfeeding after the milk supply is established (roughly 6 weeks postpartum), per the CDC Medical Eligibility Criteria for Contraceptive Use. The levonorgestrel IUD is an excellent option for postpartum women with endometriosis who need both contraception and symptom control.

Contraception requirements on specific agents

• Elagolix 150 mg once daily: non-hormonal barrier method or copper IUD required.
• Elagolix 200 mg twice daily: same as above; do not rely on COCs.
• Leuprolide acetate: non-hormonal contraception required; ovulation can return quickly after stopping.
• GnRH antagonists in general: leuprolide depot 3.75 mg monthly does not provide reliable contraception.

Who This Is Right For, and Who Should Take a Different Path

Women for whom empiric medical therapy is appropriate

You fit the empiric treatment profile if you have classic symptoms (cyclic pelvic pain, dysmenorrhea, deep dyspareunia, painful defecation or urination timed with menses), no desire for immediate pregnancy, no findings on imaging that require surgical intervention (such as an endometrioma larger than 4 cm or suspected bowel involvement), and no red flags for malignancy. Starting a COC or progestin-only agent without laparoscopy is reasonable, supported by ESHRE 2022.

Women who should not delay laparoscopy

Surgery should not be deferred if you have an ovarian endometrioma larger than 4 cm, suspected deep infiltrating disease affecting the bowel or ureter, infertility with a plan to conceive within 6-12 months, failed empiric medical therapy after 3-6 months, or diagnostic uncertainty about whether the mass is benign. ACOG and ASRM are aligned here.

Women with PCOS and co-existing endometriosis

This combination is underrecognized. Holoch 2014 estimated co-occurrence at roughly 5% of women with either condition, though the true prevalence may be higher because diagnostic criteria overlap. The shared hormonal environment (androgen excess in PCOS, estrogen dominance in endometriosis) creates diagnostic difficulty. COCs address both conditions' primary symptoms, which simplifies management.

Women approaching perimenopause with longstanding disease

Continuing GnRH agonist therapy into perimenopause accelerates bone loss on an already-vulnerable skeleton. Transition to a progestin-dominant approach or surgical menopause with appropriate MHT is a better strategy for most women in this group.

Evidence Gaps That Affect Your Care

Women have been systematically underrepresented in pain and surgical trials, and endometriosis research carries its own additional gaps.

Most endometriosis trials use pain scores as endpoints rather than quality of life, return to work, or sexual function measures that women consistently report as their primary concerns. Denny 2004 found that women with endometriosis rated the impact on sexual relationships as equally important to pain severity, yet sexual function outcomes appear in fewer than 20% of published trials.

Racial and ethnic disparities in diagnosis are documented but poorly studied. Black women are diagnosed with endometriosis at significantly lower rates than white women in population studies, despite similar or higher symptom burden, a finding Bougie 2019 attributes to both clinician bias and differential healthcare access. None of the three major guidelines includes race-specific diagnostic or treatment recommendations.

Long-term data on elagolix beyond 24 months is absent. The ELARIS extension trials ran to 12 months; bone density data beyond that point is extrapolated, not measured.

What an Ideal Guideline Would Say (and Current Ones Do Not)

"The field needs a single international consensus that addresses endometriosis across the full female lifespan, not just the reproductive years, and that specifically includes perimenopausal management, postmenopausal MHT protocols, and race-stratified diagnostic thresholds," said Dr. Rachel Goldberg, WomanRx OB-GYN reviewer and reproductive endocrinologist, in her editorial review of this article. "Until that consensus exists, women need to actively ask their providers which guideline they are following and why."

No current guideline addresses adolescent endometriosis in sufficient depth. ACOG published a Committee Opinion on endometriosis in adolescents (No. 760) in 2018, acknowledging that cyclic pelvic pain in teenagers is frequently dismissed for years before endometriosis is considered. The average age at onset of symptoms is 12-14 years; the average age at diagnosis remains in the mid-20s.

FAQ